DE60204067D1 - Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen - Google Patents

Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen

Info

Publication number
DE60204067D1
DE60204067D1 DE60204067T DE60204067T DE60204067D1 DE 60204067 D1 DE60204067 D1 DE 60204067D1 DE 60204067 T DE60204067 T DE 60204067T DE 60204067 T DE60204067 T DE 60204067T DE 60204067 D1 DE60204067 D1 DE 60204067D1
Authority
DE
Germany
Prior art keywords
xanthenone
mammal
acetic acid
hyperproliferative tissue
photodynamic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60204067T
Other languages
English (en)
Other versions
DE60204067T2 (de
Inventor
David A Bellnier
Thomas J Dougherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of DE60204067D1 publication Critical patent/DE60204067D1/de
Publication of DE60204067T2 publication Critical patent/DE60204067T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
DE60204067T 2001-03-07 2002-02-28 Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen Expired - Fee Related DE60204067T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US801163 1991-11-26
US09/801,163 US6495585B2 (en) 2001-03-07 2001-03-07 Method for treating hyperproliferative tissue in a mammal

Publications (2)

Publication Number Publication Date
DE60204067D1 true DE60204067D1 (de) 2005-06-16
DE60204067T2 DE60204067T2 (de) 2006-01-26

Family

ID=25180358

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60204067T Expired - Fee Related DE60204067T2 (de) 2001-03-07 2002-02-28 Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen

Country Status (5)

Country Link
US (1) US6495585B2 (de)
EP (1) EP1238666B1 (de)
JP (1) JP2002325853A (de)
AT (1) ATE295163T1 (de)
DE (1) DE60204067T2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
USRE39094E1 (en) 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
JP2002534483A (ja) * 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション 代謝性骨障害または骨転移のための治療的組成物
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
US8180444B2 (en) * 2007-06-22 2012-05-15 Biolitec Pharma Marketing Ltd Enhanced PhotoDynamic Therapy with immune system assist
WO2010045551A1 (en) * 2008-10-17 2010-04-22 Concert Pharmaceuticals, Inc. Xanthenone-4-acetic acid derivatives
CN109289048B (zh) * 2018-08-08 2021-05-25 南京工业大学 一种肿瘤血管阻断协同光治疗试剂及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
GB9308166D0 (en) * 1993-04-20 1993-06-02 Cancer Res Campaign Tech Cancer therapy

Also Published As

Publication number Publication date
DE60204067T2 (de) 2006-01-26
EP1238666A2 (de) 2002-09-11
EP1238666A3 (de) 2004-01-07
JP2002325853A (ja) 2002-11-12
ATE295163T1 (de) 2005-05-15
US20020128303A1 (en) 2002-09-12
EP1238666B1 (de) 2005-05-11
US6495585B2 (en) 2002-12-17

Similar Documents

Publication Publication Date Title
ATE497778T1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
DE60200774D1 (de) Mikrobizide und algizide Zusammensetzung, mikrobizides und algizides Verfahren für die Behandlung eines Wassersystems und Verfahren, um eine mikrobizide und algizide Zusammensetzung herzustellen
ATE426405T1 (de) Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
DE60204067D1 (de) Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen
EP2567705A3 (de) Verfahren zur Behandlung kognitiver Dysfunktion durch Modulation des Energiestoffwechsels des Gehirns
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE602005002461D1 (de) Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung, die dieses enthalten
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE60130030D1 (de) Verfahren zur behandlung von glaukom
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE508107T1 (de) Verfahren zur herstellung von gabapentin
DE602004003173D1 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
DE50108711D1 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE274927T1 (de) Zusammensetzungen enthaltend monoperphthalatsäure zur behandlung von kontaktlinsen
RU2001135372A (ru) Способ лечения длительно незаживающей эрозии и язвы роговицы
RU2005118300A (ru) Способ лечения пародонтита
DE50007406D1 (de) Verfahren zur reduzierung von schadorganismen in wasserströmen
EA200400783A1 (ru) Средство для радикального лечения опухолей, воспалительных процессов, грибковых инфекций и других заболеваний тканей, их диагностика и профилактика и метод его применения
RU2002112569A (ru) Способ лечения детей с посттравматическим арахноидитом радоновыми ваннами в комплексе с электромагнитным полем низкой частоты от аппарата "ИНФИТО"
DE60306828D1 (de) Vorrichtung für Behandlung eines Tumors im zentralen Nervensystem
ATE418535T1 (de) Verbessertes verfahren zur herstellung von gabapentin
ATE287709T1 (de) Verwendung eines protoporphyrin ix precursor zur behandlung von dermatophytosen und malaria nach photoaktivierung von diesem besagten protoporphyrin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee